Engelman et al. [12] constructed lung cancer cell lines resistant to Erlotinib and found that MET amplification was detected in about 22% of the samples, suggesting that MET amplification may be one of the important factors leading to Erlotinib resistance in lung cancer cell lines. This evidence concerns the gene MET and lung cancer.